- Home
- FORA vs TCRX Comparison
FORA vs TCRX Comparison
Compare FORA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- TCRX
- Stock Information
- Founded
- FORA 2014
- TCRX 2018
- Country
- FORA United States
- TCRX United States
- Employees
- FORA N/A
- TCRX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- TCRX Health Care
- Exchange
- FORA Nasdaq
- TCRX Nasdaq
- Market Cap
- FORA 69.4M
- TCRX 64.1M
- IPO Year
- FORA N/A
- TCRX 2021
- Fundamental
- Price
- FORA $2.11
- TCRX $0.98
- Analyst Decision
- FORA
- TCRX Strong Buy
- Analyst Count
- FORA 0
- TCRX 7
- Target Price
- FORA N/A
- TCRX $8.50
- AVG Volume (30 Days)
- FORA 39.0K
- TCRX 1.1M
- Earning Date
- FORA 11-14-2025
- TCRX 11-12-2025
- Dividend Yield
- FORA N/A
- TCRX N/A
- EPS Growth
- FORA N/A
- TCRX N/A
- EPS
- FORA N/A
- TCRX N/A
- Revenue
- FORA $28,106,911.00
- TCRX $8,423,000.00
- Revenue This Year
- FORA $47.82
- TCRX $255.18
- Revenue Next Year
- FORA $10.11
- TCRX N/A
- P/E Ratio
- FORA N/A
- TCRX N/A
- Revenue Growth
- FORA 37.47
- TCRX N/A
- 52 Week Low
- FORA $1.64
- TCRX $0.96
- 52 Week High
- FORA $4.03
- TCRX $4.94
- Technical
- Relative Strength Index (RSI)
- FORA 44.32
- TCRX 28.55
- Support Level
- FORA $2.05
- TCRX $0.96
- Resistance Level
- FORA $2.30
- TCRX $1.25
- Average True Range (ATR)
- FORA 0.10
- TCRX 0.13
- MACD
- FORA -0.01
- TCRX -0.02
- Stochastic Oscillator
- FORA 28.78
- TCRX 4.00
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.